Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Autolus Therapeutics plc (AUTL)

1.6100 +0.0050 (+0.31%)
As of 2:03:36 PM EDT. Market Open.
Chart Range Bar
Loading chart for AUTL
  • Previous Close 1.6050
  • Open 1.6100
  • Bid 1.3800 x 200
  • Ask 2.0800 x 200
  • Day's Range 1.6100 - 1.6800
  • 52 Week Range 1.1750 - 2.7000
  • Volume 390,023
  • Avg. Volume 1,550,746
  • Market Cap (intraday) 428.491M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.0900
  • Earnings Date (est.) Aug 7, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.71

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

www.autolus.com

752

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 6/25/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

AUTL
18.27%
MSCI WORLD (^990100-USD-STRD)
7.22%

1-Year Return

AUTL
29.07%
MSCI WORLD (^990100-USD-STRD)
20.25%

3-Year Return

AUTL
36.86%
MSCI WORLD (^990100-USD-STRD)
0.00%

5-Year Return

AUTL
76.53%
MSCI WORLD (^990100-USD-STRD)
57.03%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 26.22M
Earnings -71.6M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-80M
-60M
-40M
-20M
0
20M

Analyst Insights

View More

Analyst Price Targets

5.00
8.71 Average
1.6100 Current
11.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/14/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 9 -> 10

Statistics

View More

Valuation Measures

Annual
As of 6/24/2026
  • Market Cap

    423.17M

  • Enterprise Value

    273.69M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.57

  • Price/Book (mrq)

    3.89

  • Enterprise Value/Revenue

    2.95

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -22.27%

  • Return on Equity (ttm)

    -29.62%

  • Revenue (ttm)

    1.08M

  • Net Income Avi to Common (ttm)

    -53.28M

  • Diluted EPS (ttm)

    -1.0900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    217.45M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.6100 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: